Predicting Tumor Responses to Gefitinib and Erlotinib

Podobne zapisy

• Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
  Wydane: (2012)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  od: Nishino, Mizuki, i wsp.
  Wydane: (2016)
• Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells
  od: Bachawal, Sunitha V, i wsp.
  Wydane: (2010)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  od: Zakowski, Maureen F., i wsp.
  Wydane: (2009)
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  od: Pao, William, i wsp.
  Wydane: (2005)